drug development,
in context

novel medicines for patients
with hormone driven cancers 

Home Banner.jpg

Our Focus

Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers.

Lead Program

Apristor is an investigational medicine for breast, ovarian, and endometrial cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor.

Sharing our Values

We have grit, like the people we help.

latest news

AACR Annual Meeting 2019
March 29 - April 3
Atlanta, GA

Needham Healthcare Conference
April 8-9
New York, NY